Brokers Offer Predictions for Dermira Inc’s FY2018 Earnings (DERM)

Dermira Inc (NASDAQ:DERM) – Equities researchers at Cantor Fitzgerald dropped their FY2018 EPS estimates for shares of Dermira in a note issued to investors on Tuesday, Zacks Investment Research reports. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will post earnings per share of ($4.49) for the year, down from their prior forecast of ($3.71). Cantor Fitzgerald currently has a “Buy” rating and a $20.00 target price on the stock.

How to Become a New Pot Stock Millionaire

DERM has been the subject of a number of other research reports. Zacks Investment Research lowered Dermira from a “hold” rating to a “sell” rating in a research note on Thursday, March 8th. Mizuho lowered Dermira from a “buy” rating to a “neutral” rating in a research note on Monday, March 5th. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research report on Tuesday, January 30th. Guggenheim assumed coverage on Dermira in a research report on Tuesday, December 5th. They issued a “buy” rating for the company. Finally, Leerink Swann lifted their target price on Dermira from $42.00 to $48.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 17th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $32.71.

NASDAQ DERM traded down $0.33 during mid-day trading on Friday, reaching $7.66. 1,254,700 shares of the company’s stock traded hands, compared to its average volume of 1,599,924. Dermira has a 1-year low of $7.53 and a 1-year high of $35.76. The company has a quick ratio of 5.28, a current ratio of 5.28 and a debt-to-equity ratio of 1.87. The firm has a market cap of $334.16, a PE ratio of -1.74 and a beta of 1.54.

Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.09). Dermira had a negative net margin of 6,678.29% and a negative return on equity of 62.07%. The business had revenue of $1.34 million for the quarter, compared to analyst estimates of $1.10 million.

In related news, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total transaction of $499,288.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.07, for a total value of $81,210.00. Following the transaction, the insider now owns 5,802 shares of the company’s stock, valued at approximately $157,060.14. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,758 shares of company stock valued at $728,459. Insiders own 13.30% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC boosted its position in Dermira by 0.3% during the 3rd quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock valued at $71,300,000 after purchasing an additional 7,746 shares during the period. Millennium Management LLC acquired a new position in Dermira during the 4th quarter valued at approximately $25,084,000. Franklin Resources Inc. acquired a new position in Dermira during the 4th quarter valued at approximately $24,820,000. State Street Corp boosted its position in Dermira by 38.4% during the 2nd quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock valued at $23,946,000 after purchasing an additional 228,093 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in Dermira by 621.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock valued at $19,248,000 after purchasing an additional 614,138 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Brokers Offer Predictions for Dermira Inc’s FY2018 Earnings (DERM)” was first published by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://theenterpriseleader.com/2018/04/02/research-analysts-set-expectations-for-dermira-incs-fy2018-earnings-derm.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Get a free copy of the Zacks research report on Dermira (DERM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply